ESMO Breast 2024 | PF-07220060, a novel oral CDK4-selective inhibitor, in HR+/HER2- mBC

Timothy Yap, MBBS, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents updated safety and efficacy data from a Phase I/IIa study (NCT04557449) of PF-07220060, a novel oral CDK4-selective inhibitor, in combination with endocrine therapy (ET) for patients with HR+/HER2- metastatic breast cancer (mBC), who progressed on prior CDK4/6 inhibitors and ET. The combination showed promising efficacy, irrespective of ESR1 or PI3K pathway mutations, and the novel drug was well tolerated. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.